| Inflammation is a potential risk factor of voriconazole overdose in hematological patients E Gautier‐Veyret, A Truffot, S Bailly, X Fonrose, A Thiebaut‐Bertrand, ... Fundamental & Clinical Pharmacology 33 (2), 232-238, 2019 | 49 | 2019 |
| Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates F Simon, E Gautier-Veyret, A Truffot, M Chenel, L Payen, ... Pharmaceutical Research 38, 415-428, 2021 | 27 | 2021 |
| SARS-CoV-2 variants in immunocompromised patient given antibody monotherapy A Truffot, J Andréani, M Le Maréchal, A Caporossi, O Epaulard, R Germi, ... Emerging infectious diseases 27 (10), 2725, 2021 | 23 | 2021 |
| Calreticulin mutations in myeloproliferative neoplasms: comparison of three diagnostic methods JH Park, M Sevin, S Ramla, A Truffot, T Verrier, D Bouchot, M Courtois, ... PloS one 10 (10), e0141010, 2015 | 22 | 2015 |
| Virological markers in Epstein–Barr virus-associated diseases J Lupo, A Truffot, J Andreani, M Habib, O Epaulard, P Morand, R Germi Viruses 15 (3), 656, 2023 | 13 | 2023 |
| Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits A Truffot, JF Jourdil, B Seitz-Polski, P Malvezzi, V Brglez, ... Clinical Biochemistry 87, 60-66, 2021 | 13 | 2021 |
| Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis A Truffot, E Gautier‐Veyret, A Baillet, JF Jourdil, F Stanke‐Labesque, ... Fundamental & Clinical Pharmacology 35 (6), 1090-1099, 2021 | 6 | 2021 |
| Inhibition of voriconazole metabolism by meropenem: a role for inflammation? A Truffot, A Thiebaut-Bertrand, C Chapuis, F Stanke-Labesque, ... Clinical Infectious Diseases 66 (10), 1643-1644, 2018 | 6 | 2018 |
| Comparison of Elecsys and Liaison immunoassays to determine Epstein–Barr virus serological status using further diagnostic approaches to clarify discrepant results J Lupo, M Tsougaev, S Blachier, G Chovelon, A Truffot, C Leroy, J Giai, ... Journal of Medical Virology 95 (1), e28166, 2023 | 5 | 2023 |
| Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis N Van den Berghe, A Truffot, M Peeters, G Compernolle, E Brouwers, ... Journal of Pharmaceutical and Biomedical Analysis 189, 113433, 2020 | 5 | 2020 |
| Conversion to mTOR-inhibitors plus IV immunoglobulins in kidney-transplant recipients with BKV infection: a retrospective comparative study C Vela, T Jouve, E Chevallier, F Imerzoukene, R Germi, M Le Marechal, ... Journal of Clinical Medicine 11 (24), 7292, 2022 | 4 | 2022 |
| Quantification of belatacept by liquid chromatography-tandem mass spectrometry in human plasma: Application to a pharmacokinetic study in renal transplant recipients A Truffot, JF Jourdil, E Veyret-Gautier, J Noble, T Jouve, P Malvezzi, ... Clinical Biochemistry 113, 17-20, 2023 | 2 | 2023 |
| Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization A Truffot, T Jouve, J Noble, B Bardy, P Malvezzi, L Rostaing, ... Journal of Clinical Medicine 11 (1), 91, 2021 | 2 | 2021 |
| Evaluation of torque Teno virus DNA load as a predictive biomarker in kidney transplant recipients converted from calcineurin inhibitors to Belatacept L Cabezas, A Truffot, R Germi, M Bugnazet, P Malvezzi, M Gnesotto, ... Kidney International Reports 9 (6), 1718-1729, 2024 | 1 | 2024 |
| Use of RT-PCR thermocycling program for the quantification of DNA viruses in a single run with RNA viruses: Example of Altona RealStar® HSV or VZV PCR kits J Andreani, J Lupo, B Nemoz, A Truffot, S Larrat, P Morand, R Germi Infectious Diseases Now 52 (8), 453-455, 2022 | 1 | 2022 |
| Consumption of cannabinoid derivatives, 5F-AKB48, by electronic cigarette vaping, at the origin of psychotic decompensation? T Buisson, A Pouchon, A Truffot, M Lepelley, B Revol, M Bartoli, ... THERAPIE 72 (1), 157-158, 2017 | 1* | 2017 |
| Results of a French external quality assessment program for Epstein Barr virus serology. J Lupo, A Truffot, R Germi, AK Faure, P Morand, E Francois-Burg Diagnostic Microbiology and Infectious Disease 109 (3), 116345-116345, 2024 | | 2024 |
| Les marqueurs virologiques des cancers associés au virus d’Epstein-Barr J Lupo, A Truffot, J Andreani, M Habib, R Germi, P Morand Revue Francophone des Laboratoires 2024 (558), 35-45, 2024 | | 2024 |
| Epstein-Barr Virus Encephalitis: A Review of Case Reports from the Last 25 Years M Peuchmaur, J Voisin, M Vaillant, A Truffot, J Lupo, P Morand, ... Microorganisms 11 (12), 2825, 2023 | | 2023 |
| Fatal HSV-2 primary infection most likely acquired by kidney transplantation: A case report A Truffot, J Noble, A Dartevel, E Chevalier, C Dard, D Giovannini, ... International Journal of Antimicrobial Agents 61 (5), 106769, 2023 | | 2023 |
